FREENOME LIMITED

1. FREENOME LIMITED 2023-05-22 → present
2. ONCIMMUNE LIMITED 2006-02-14 → 2023-05-22
3. ONC-IMMUNE LIMITED 2003-01-09 → 2006-02-14
4. M&R 877 LIMITED 2002-12-03 → 2003-01-09

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Standalone (parent only)

Auditor

Gravita II LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“As at the year end, the Company reported net liabilities of £202,000 (2023: net assets of £26,000 as restated), which includes amounts due to the parent company, Freenome Holdings Inc, of £1,169,000 (2023: £840,000). The Company is reliant on its parent company to provide continued financial support to enable the Company to meet its financial obligations as and when they fall due. The Directors have received a letter of support from the parent company confirming their intention to provide the necessary financial support to the company as long as it remains a subsidiary of Freenome Holdings Inc, to enable the company to continue its business activities and settle its external liabilities as they fall due. Having made suitable enquiries, the Directors consider that the parent company has and will continue to have sufficient resources to provide such support in a range of future cash flow scenarios. The Director has therefore prepared the 2024 financial statements on a going concern basis.”

Significant events

• “The Company was known as Oncimmune Limited until 22 May 2023.”
• “During the prior period the Company reduced the scope of an existing property lease which was recorded as a lease modification. The net impact was a gain on modification of £44k which was recorded in profit or loss. The property lease expired in October 2024 and a new lease is under negotiation.”
• “A Right of Use Asset purchased in the prior period was reclassed from Property, Plant and Equipment and the prior year restated.”
• “The subsidiary FN (Americas) LLC was dissolved on 14 July 2023 and the loan to that subsidiary was written off in full.”
• “The previous parent company, Oncimmune Holdings plc, granted options to certain Directors and employees of the Company in respect of ordinary shares in Oncimmune Holdings plc. All such options lapsed on the sale of the company to Freenome Holdings, Inc on 19 May 2023. No options were exercised or issued in the period and there were no options in issue at 31 December 2024.”
• “During the year, it was identified that certain leased equipment had been incorrectly classified as property, plant and equipment instead of as a right-of-use asset when it was acquired in 2023. Additionally, it should have been depreciated over the lease term. As a result, the comparative figures have been restated.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.